Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant patient samples.
Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant patient samples.
复制标题
DOI：
10.1080/00952990903125235
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
Fischer G
中科院分区：
文献类型：
--
作者：
Jones HE;Heil SH;O'Grady KE;Martin PR;Kaltenbach K;Coyle MG;Stine SM;Selby P;Arria AM;Fischer G
Little is known about the prevalence and severity of smoking in pregnant opioid dependent patients. To first characterize the prevalence and severity of smoking in pregnant patients screened for a randomized controlled trial, MOTHER (Maternal Opioid Treatment: Human Experimental Research), comparing two agonist medications; and second, to compare the MOTHER screening sample to published samples of other pregnant and/or substance use disordered patients. Pregnant women (N=108) screened for entry into an agonist medication comparison study were retrospectively compared on smoking variables to samples of pregnant methadone-maintained patients (N=50), pregnant opioid or cocaine dependent patients (N =240), non-pregnant methadone-maintained women (N =75), and pregnant non-drug-addicted patients (N=1,516). Of screened patients, 88% (n = 95) smoked for a mean of 140 months (SD=79.0) starting at a mean age of 14 (SD=3.5). This rate was similar to substance use disordered patients and significantly higher compared to general pregnant patients (88% v. 22%, p < .001). Aggressive efforts are needed to reduce/eliminate smoking in substance-abusing pregnant women.
